GLP-1 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
FIFA.com shortlisted 12 goals for users to vote on as the goal of the tournament. The award was won by Cape Verde's Sidny Lopes Cabral for his equalizing goal in extra time during the round of 32 match against Argentina. Additionally, a "Superior Player of the Match" award was presented after each game to the player who delivered the most outstanding performance in, and had the greatest impact on, that match, as decided by a public online vote conducted by FIFA. The award was sponsored by Michelob Ultra. Muslim players, such as Mohamed Salah and Lamine Yamal, received a brandless trophy, out of respect for Islam's views on alcohol. Outside of the FIFA awards, Messi was named the tournament's best player by the International Federation of Football History and Statistics (IFFHS), who cited his eight goals and four assists across seven appearances as the basis for the distinction.
Schoenheimer's scientific work contributed to biochemistry and metabolic studies, with his most significant work being the application of isotopes to the study of intermediary metabolism. Schoenheimer's earlier scientific work in the 1920s centered on the physiology and pathology of sterols.
=== Analogs === Some analog substances have been created which mimic caffeine's properties with either function or structure or both. Of the latter group are the xanthines DMPX and 8-chlorotheophylline, which is an ingredient in dramamine. Members of a class of nitrogen substituted xanthines are often proposed as potential alternatives to caffeine. Many other xanthine analogues constituting the adenosine receptor antagonist class have also been elucidated. Some other caffeine analogs:
Rimonabant was discovered and developed by Sanofi-Aventis. On 21 June 2006, the European Commission approved the sale of rimonabant in the then-25-member European Union as a prescription drug for use in conjunction with diet and exercise for patients with a body mass index (BMI) greater than 30 kg/m2, or patients with a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia. It was first in its class to be approved anywhere in the world. Rimonabant was submitted to the Food and Drug Administration (FDA) for approval in the United States in 2005; in 2007, the FDA's Endocrine and Metabolic Drugs Advisory Committee (EMDAC) concluded that Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval. The application was deemed not-approvable by FDA, and the company cancelled plans for a re-submission. The drug was approved in Brazil in April 2007. In October 2008, the European Medicines Agency recommended the suspension of Acomplia after the Committee for Medicinal Products for Human Use (CHMP) had determined that the risks of Acomplia outweighed its benefits due to the risk of serious psychiatric problems, including suicide. In November 2008 an advisory committee in Brazil recommended suspension as well, and that month Sanofi-Aventis suspended sale of the drug worldwide. The EMA approval was withdrawn in January 2009. In 2009 India prohibited the manufacture and sale of the drug.
Sources: en.wikipedia.org
26 December Sid Ashton, accountant, chief executive of Te Rūnanga o Ngāi Tahu (1993–2002), chair of the Charities Commission (2005–2011) (born 1936). Ken Thompson, police officer, Commissioner of Police (1983–1987) (born 1932). 27 December Dave Leathwick, parasitologist (AgResearch) (born 1955). Garrick Tremain, cartoonist (Otago Daily Times) and painter (born 1941).
Pritzker is seeking a third term as governor of Illinois in 2026. He is viewed as a potential Democratic contender for president of the United States, according to NBC News and The Wall Street Journal. He has declined to rule out a presidential run in 2028.
The Liberal Party grew out of the Whigs, who had their origins in an aristocratic faction in the reign of Charles II, and the early 19th century Radicals. The Whigs were in favour of reducing the power of the Crown and increasing the power of Parliament. Although their motives in this were originally to gain more power for themselves, the more idealistic Whigs gradually came to support an expansion of democracy for its own sake. The great figures of reformist Whiggery were Charles James Fox (died 1806) and his disciple and successor Earl Grey. After decades in opposition, the Whigs returned to power under Grey in 1830 and carried the First Reform Act in 1832. The Reform Act was the climax of Whiggism, but it also brought about the Whigs' demise. The admission of the middle classes to the franchise and to the House of Commons led eventually to the development of a systematic middle-class liberalism and the end of Whiggery, although for many years reforming aristocrats held senior positions in the party. In the years after Grey's retirement, the party was led first by Lord Melbourne, a fairly traditional Whig, and then by Lord John Russell, the son of a Duke but a crusading radical, and by Lord Palmerston, a renegade Irish Tory and essentially a conservative, although capable of radical gestures. As early as 1839, Russell had adopted the name of "Liberals"; in reality, his party was a loose coalition of Whigs in the House of Lords and Radicals in the Commons.
Sources: en.wikipedia.org
=== International locations === The first location outside of North America opened in the United Kingdom on July 4, 2013, in London on Long Acre in Covent Garden. The chain now has more than 170 restaurants in the United Kingdom. In 2017, Five Guys opened its first restaurants in Germany, with a branch in Frankfurt and another in Essen. Five Guys opened its first Korean store in Gangnam, Seoul in 2023, with a countdown shout, and expanded to four branches in Seoul. In 2021, Five Guys opened their first location in Australia. The chain also has plans to expand into New Zealand. In 2025, Five Guys announced that it would open their first restaurant in Denmark, at Fisketorvet, a shopping mall in Copenhagen. In 2026, the number of stores per country was as follows:
Thy-1 membrane glycoprotein or CD90 (Cluster of Differentiation 90) is a protein that in humans is encoded by the THY1 gene. It is a 25–37 kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored conserved cell surface protein with a single V-like immunoglobulin domain, originally discovered as a thymocyte antigen. Thy-1 can be used as a marker for a variety of stem cells and for the axonal processes of mature neurons. Structural study of Thy-1 led to the foundation of the Immunoglobulin superfamily, of which it is the smallest member, and led to some of the initial biochemical description and characterization of a vertebrate GPI anchor and also the first demonstration of tissue specific differential glycosylation.
==== Solid state ==== Few neptunium(III) coordination compounds are known, because Np(III) is readily oxidized by atmospheric oxygen while in aqueous solution. However, sodium formaldehyde sulfoxylate can reduce Np(IV) to Np(III), stabilizing the lower oxidation state and forming various sparingly soluble Np(III) coordination complexes, such as Np2(C2O4)3·11H2O, Np2(C6H5AsO3)3·H2O, and Np2[C6H4(OH)COO]3. Many neptunium(IV) coordination compounds have been reported, the first one being (Et4N)Np(NCS)8, which is isostructural with the analogous uranium(IV) coordination compound. Other Np(IV) coordination compounds are known, some involving other metals such as cobalt (CoNp2F10·8H2O, formed at 400 K) and copper (CuNp2F10·6H2O, formed at 600 K). Complex nitrate compounds are also known: the experimenters who produced them in 1986 and 1987 obtained single crystals by slow evaporation of the Np(IV) solution at ambient temperature in concentrated nitric acid and excess 2,2′-pyrimidine. The coordination chemistry of neptunium(V) has been extensively researched due to the presence of cation–cation interactions in the solid state, which had been already known for actinyl ions. Some known such compounds include the neptunyl dimer Na4(NpO4)2C12O12·8H2O and neptunium glycolate, both of which form green crystals. Neptunium(VI) compounds range from the simple oxalate NpO2C2O4 (which is unstable, usually becoming Np(IV)) to such complicated compounds as the green (NH4)4NpO2(CO3)3.
== Later research == Reichelt published a number of papers concluding that autistic children excrete higher levels of peptides in their urine, as well as that such peptides may cause autistic gaze aversion; specifically, by interfering with corticothalamocortical processing of visual stimuli. As a result of this theory, others, particularly Panksepp, have speculated that opioid antagonists such as naloxone and naltrexone may be useful in the treatment of autism. In addition, Christopher Gillberg of the University of Gothenburg has published some studies showing that animals treated with opiates exhibit less clinging, in line with the behavior of autistic children, who, his research has also shown, "do not seem concerned when their parents are not near" and "exhibit less crying than infants without autism", and has also linked an excess of endogenous opioids to stereotypic (i.e. repetitive) behavior. However, more recently, two studies were published which failed to find a difference in levels of peptides in the urine of autistic children as opposed to those without autism. A 2009 review found that no evidence exists that urinary peptide levels are correlated with gut permeability.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.